Consensus Tyra Biosciences, Inc.

Stocks

TYRA

US90240B1061

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 13:18:02 2026-09-30 EDT			5-day change	1st Jan Change
21.88 ^USD	-0.48%		-5.12%	-16.17%

09-22	Oppenheimer Adjusts Price Target on Tyra Bioscience to $40 From $50, Keeps Outperform Rating	MT
09-14	Tyra Bioscience Shares Rise After Pricing $400 Million Offering	MT

Evolution of the Average Target: Tyra Biosciences, Inc.

Evolution of the Target Price: Tyra Biosciences, Inc.

Changes in Analyst Recommendations: Tyra Biosciences, Inc.

3e2f3cd385a8f6a90.sEvX2pBgT5WmrSofphmdJQNi82X1LUdQogKr00ip8I0.gHyB7ecwCfLR1V5G81_ZbWcvkQSta3UZ6lTOlBvRr-zieOS7wRUL39LKZw~bd4913e1bc76b791cbd43ee8b89ddfc1

Analysts' recommendations: Tyra Biosciences, Inc.

09-22	Oppenheimer Adjusts Price Target on Tyra Bioscience to $40 From $50, Keeps Outperform Rating	MT
08-11	BofA Adjusts Price Target on Tyra Bioscience to $39 From $42	MT
06-10	Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says	MT
06-10	BofA Securities Raises Price Target on Devon Energy to $42 From $37, Buy Rating Kept	MT
04-15	Guggenheim Initiates Tyra Bioscience at Buy With $54 Price Target	MT
04-06	Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target	MT
02-24	Cantor Fitzgerald Initiates Tyra Bioscience at Overweight	MT
02-12	Wedbush Raises Price Target on Tyra Bioscience to $53 From $37, Keeps Outperform Rating	MT
02-10	William Blair Initiates Tyra Bioscience at Outperform	MT
02-03	Oppenheimer Adjusts Price Target on Tyra Bioscience to $50 From $36, Maintains Outperform Rating	MT
01-28	Barclays Initiates Coverage on Tyra Bioscience With Overweight Rating, $59 Price Target	MT
12-16	Wedbush Raises Price Target on Tyra Bioscience to $37 From $30, Adds Stock to Best Ideas List, Keeps Outperform Rating	MT
25-09-10	Oppenheimer Adjusts Price Target on Tyra Bioscience to $36 From $30, Maintains Outperform Rating	MT
25-09-03	Raymond James Initiates Tyra Bioscience at Strong Buy With $35 Price Target	MT
24-10-18	BofA Securities Upgrades Tyra Biosciences to Buy From Neutral, Adjusts Price Target to $31 From $22	MT
24-09-19	Oppenheimer Adjusts Tyra Biosciences Price Target to $33 From $25, Maintains Outperform Rating	MT
24-08-15	Piper Sandler Initiates Tyra Biosciences at Overweight With $33 Price Target	MT
24-08-08	Oppenheimer Adjusts Tyra Biosciences Price Target to $25 From $28, Maintains Outperform Rating	MT
24-05-13	Oppenheimer Adjusts Tyra Biosciences Price Target to $28 From $25, Maintains Outperform Rating	MT
24-03-20	HC Wainwright Adjusts Tyra Biosciences Price Target to $23 From $19, Maintains Buy Rating	MT
24-02-05	Wedbush Lifts Tyra Biosciences' PT to $28 From $27, Tweaks Financing Assumptions; Keeps Outperform Rating	MT
23-11-08	HC Wainwright Adjusts Price Target on Tyra Biosciences to $19 From $20, Maintains Buy Rating	MT
23-08-11	HC Wainwright Adjusts Price Target on Tyra Biosciences to $20 From $17, Keeps Buy Rating	MT
23-06-30	Wedbush Starts Tyra Biosciences at Outperform With $27 Price Target, Says Pipeline Likely to Drive Significant Additional Upside	MT
23-03-07	HC Wainwright Adjusts Price Target on Tyra Biosciences to $17 From $15, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TYRA BIOSCIENCES, INC.					+115.9%
	WUXI APPTEC CO., LTD.					+16.44%
	ARGENX SE					+22.14%
	LONZA GROUP AG					+17.84%
	IQVIA HOLDINGS INC.					+6.62%
	REVOLUTION MEDICINES, INC.					+25.91%
	BEONE MEDICINES AG					+18.49%
	CELLTRION, INC.					+49.69%
	WUXI BIOLOGICS (CAYMAN) INC.					+8.86%
	INSMED INCORPORATED					+71.01%
	Average					+35.29%
	Weighted average by Cap.					+23.51%